Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.64 |
| ▸ | CTSS | P25774 | 5/20 | 0.64 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | GRN | P28799 | 1/20 | 0.43 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24298421 | 1.00 | CTSK (0.64) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL952036 | 1.00 | CTSK (0.64) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL3814592 | 0.97 | CTSK (0.68) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL3819388 | 0.97 | CTSK (0.68) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL3814600 | 0.97 | CTSK (0.68) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL8283416 | 0.95 | CTSK (0.70) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL16945 | 0.95 | CTSK (0.70) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL21427213 | 0.95 | CTSK (0.70) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL21427220 | 0.95 | CTSK (0.70) | CTSKCTSSAAK1IDO1PPARA | |
| SCHEMBL9742302 | 0.95 | CTSK (0.70) | CTSKCTSSAAK1IDO1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | PARDES BIOSCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4702033-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | PFIZER INC. (US) | 2025-03-27 | — | — | US | disclosed |
| EP-4516301-A2 | NITRILE-CONTAINING COMPOUNDS FOR USE AS MEDICAMENTS | Pfizer Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306790-A | Amide derivative, composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | Pardes Biosciences, Inc. (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024224086-A1 | DESMURAMYLPEPTIDE DIACIDS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| WO-2009100225-A1 | INHIBITORS OF CATHEPSIN B | VIROBAY, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009080226-A2 | HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS | SANOFIS-AVENTIS (FR) | 2009-07-02 | — | — | WO | disclosed |
| EP-2038041-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | Myriad Genetics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20080300180-A1 | Growth Hormone Secretagogue Receptor 1A Ligands | GASTROTECH PHARMA A/S (DK) | 2008-12-04 | — | — | US | disclosed |
| US-20080300180-A1 | Growth Hormone Secretagogue Receptor 1A Ligands | GASTROTECH PHARMA A/S (DK) | 2008-12-04 | — | — | US | disclosed |
| US-20080161254-A1 | HCV INHIBITORS | VIROBAY, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2007134298-A2 | THERAPEUTIC COMPOUNDS AND THEIR USE IN CANCER | MYRIAD GENETICS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2004032834-A2 | THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161254-A1 | HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | CTSK 448/4885CTSS 199/4885AAK1 2612/4885 |
| US-20260116857-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOFS | CTRC, CTRL, CTSL | CTSK 50/4885CTSS 7/4885AAK1 4588/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CTSK 4661/4885CTSS 4022/4885AAK1 4583/4885 |
| US-20250099424-A1 | Nitrile-Containing Antiviral Compounds | ACE2, NOS2, EIF2AK2 | CTSK 1493/4885CTSS 1307/4885AAK1 3995/4885 |
| US-20080300180-A1 | Growth Hormone Secretagogue Receptor 1A Ligands | GHSR, GHRHR, GIPR | CTSK 2973/4885CTSS 1399/4885AAK1 1994/4885 |
| US-20070054864-A1 | 1-[2S-(3-Tert-butylureido)-3,3-dimethylbutyryl]-4R-(7-methoxy-2-pyrazol-1-yl-quinolin-4-yloxy)-pyrrolidine-2S-carboxylic acid (1S-cyclopropylaminooxalylbutyl)amide, for example; useful in treating hepatitis C infections | HAVCR2, EIF2AK2, GTF3C1 | CTSK 694/4885CTSS 583/4885AAK1 1854/4885 |
| US-12145911-B2 | Inhibitors of cysteine proteases and methods of use thereof | CTRL, CTSV, CTSL | CTSK 43/4885CTSS 7/4885AAK1 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.